An investigation for investors in Catabasis Pharmaceuticals Inc (NASDAQ:CATB) shares over potential securities laws violations by Catabasis Pharmaceuticals was announced and NASDAQ:CATB stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 02/08/2017 -- Catabasis Pharmaceuticals Inc is under investigation over potential securities laws violations. The investigation was announced for investors in NASDAQ:CATB shares in connection certain financial statements made by Catabasis Pharmaceuticals Inc.
Investors who purchased shares of Catabasis Pharmaceuticals Inc (NASDAQ:CATB), have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call 858-779-1554.
The investigation by a law firm focuses on whether a series of statements by Catabasis Pharmaceuticals Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Cambrdige, Ma based Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. Catabasis Pharmaceuticals Inc went public in June 2016. Shares of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) reached $14.38 per share in July 2016.
On January 31, 2017, Catabasis Pharmaceuticals Inc announced top-line safety and efficacy results for Part B of the MoveDMD® trial of edasalonexent (CAT-1004) for the treatment of Duchenne muscular dystrophy (DMD).
Shares of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) declined to as low as $1.08 per share on February 1, 2017.
On February 7, 2017, NASDAQ:CATB shares closed at $1.22 per share.
Those who purchased shares of Catabasis Pharmaceuticals Inc have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego